Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($1.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.78) by $0.08, FiscalAI reports.
Here are the key takeaways from Palvella Therapeutics’ conference call:
- Positive sentiment: The FDA accepted Palvella’s QTORIN rapamycin NDA for microcystic lymphatic malformations and granted Priority Review, setting a February 28, 2027 PDUFA date. If approved, it would be the first FDA-approved treatment for the condition.
- Positive sentiment: Management cited physician research showing more than 70% of surveyed doctors expect to prescribe QTORIN rapamycin within three months of approval. The company estimates more than 30,000 diagnosed U.S. patients and says the opportunity could exceed $1 billion in peak annual U.S. sales; these are company estimates, not established results.
- Positive sentiment: Palvella said it is preparing a roughly 70-person commercial and medical team for a potential launch, including about 40 frontline sales representatives. Payer discussions have been constructive, though coverage and access remain to be established.
- Positive sentiment: The company plans to start a Phase III study of QTORIN rapamycin for cutaneous venous malformations this quarter and expects Phase II results for angiokeratomas in the second half of 2027. It also reported continued development progress for its DSAP candidate, extending its pipeline beyond the lead program.
- Negative sentiment: Palvella ended Q3 with $236.7 million in cash and said it expects funding to last deep into a potential launch, but anticipates its largest investment to date in Q4 as hiring and pre-commercial spending increase. Management cautioned that early revenue may lag demand while payer coverage, treatment-center workflows, and patient access processes are established, and it will not provide specific 2027 revenue guidance.
Palvella Therapeutics Stock Performance
Shares of NASDAQ PVLA traded up $19.07 during trading on Friday, reaching $175.92. The company had a trading volume of 502,014 shares, compared to its average volume of 237,190. Palvella Therapeutics has a twelve month low of $72.22 and a twelve month high of $176.94. The stock has a 50-day moving average price of $142.54 and a two-hundred day moving average price of $128.12.
Insider Activity at Palvella Therapeutics
In related news, COO Kathleen Goin sold 4,313 shares of the business’s stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $124.58, for a total value of $537,313.54. Following the completion of the transaction, the chief operating officer owned 2,165 shares of the company’s stock, valued at approximately $269,715.70. The trade was a 66.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director George M. Jenkins sold 7,174 shares of the company’s stock in a transaction dated Tuesday, October 13th. The shares were sold at an average price of $130.36, for a total transaction of $935,202.64. Following the completion of the transaction, the director owned 139,790 shares in the company, valued at approximately $18,223,024.40. This trade represents a 4.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,056 shares of company stock valued at $8,756,946 over the last quarter. Insiders own 17.20% of the company’s stock.
Analyst Ratings Changes
Several equities analysts recently weighed in on the company. Raymond James Financial set a $226.00 price objective on Palvella Therapeutics in a research note on Friday, October 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. Oppenheimer boosted their target price on Palvella Therapeutics from $210.00 to $232.00 and gave the stock an “outperform” rating in a research report on Friday. Truist Financial set a $207.00 target price on Palvella Therapeutics in a report on Wednesday, August 5th. Finally, Chardan Capital restated a “buy” rating and issued a $240.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $213.00.
Check Out Our Latest Stock Analysis on Palvella Therapeutics
About Palvella Therapeutics
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.
The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.
Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets.
Featured Stories
- Five stocks we like better than Palvella Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
